A prospective, randomized, open multicenter study of 0.1% tacrolimus ointment in the maintenance treatment of adult vitiligo

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057269

Enrollment

Unknown

Registered

2022-03-05

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

Group 1 :None

Group 2:Maintenance treatment for 26 weeks

Group 3:Maintenance treatment for 52 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-60 years with non-segmental vitiligo; 2. Satisfactory color recovery was achieved in the treatment of vitiligo (color recovery rate >= 75%). Leukoplakia of the face and neck with an area <= 2% BSA was selected as the target skin lesion for curative effect evaluation and maintenance treatment observation; 3. The patient knows and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with other systemic immune or neoplastic diseases; 2. Pregnant or lactating women (pregnancy tests will be carried out); 3. Allergic to tacrolimus; 4. Patients who live or work exposed to ultraviolet light or at the same time exposed to sunlight without protection; 5. Patients with topical (vitiligo lesions) or systemic combined immunosuppressive therapy or oral corticosteroid therapy.

Design outcomes

Primary

Measure	Time frame
vitiligo area scoring index, VASI;	—

Countries

China

Contacts

Public ContactAi'e Xu

Hangzhou Third People's Hospital

xuaiehz@hotmail.com+86 13906536223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026